Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk (AMG145)

This study has been completed.
Information provided by (Responsible Party):
Amgen Identifier:
First received: September 26, 2013
Last updated: September 8, 2015
Last verified: September 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2014
  Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: April 9, 2015